A single modular platform — scalable, programmable, and designed to outsmart cancer.
Our Pipeline
Liver Cancer
Leveraging ViVac’s RNA–LNP platform to trigger controlled, virus-like immune activation inside the tumor, designed to break through liver-specific immune suppression and achieve durable responses.
Ovarian Cancer
Targeting CD155-overexpressing ovarian tumors with self-limiting RNA–Lipid Nanoparticle therapy designed to reshape the tumor microenvironment and sustain immune surveillance against recurrence.
Solid Tumor X
A platform built to extend across many solid tumors, enabling broad therapeutic reach. Its modular RNA–LNP design allows precise immune activation tailored to the unique challenges of each tumor type.
Together, these programs demonstrate the versatility of ViVac’s platform — adaptable across a broad range of solid tumors where localized immune activation can achieve lasting therapeutic benefit.
Proof-of-Concept
ViVac has achieved strong early validation of its RNA–Lipid Nanoparticle platform, demonstrating proof-of-concept in vitro and confirming RNA expression and targeted tumor delivery in vivo.
